Skip to content
PeptideAgent

Pramlintide regulatory status

Current status of Pramlintide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Pramlintide?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
FDA and compounding
FDA approved product (Symlin, March 2005) for type 1 and type 2 diabetes in patients using mealtime insulin who have not achieved glucose control. It is prescription only. Because an approved product is available and not in shortage, compounding is not permitted except for a documented patient specific clinical need. Pramlintide is not on any FDA compounding bulks list and is not sold through peptide vendors in any meaningful way.
WADA
Not WADA prohibited
Access path
  1. Prescription from an endocrinologist or primary care provider filled at a retail or specialty pharmacy as Symlin.
  2. Not available through compounding pharmacies or telehealth peptide clinics.

Full Pramlintide page: evidence, dosing in the literature, and sources

How has the status of Pramlintide changed over time?

  1. FDA

    FDA approves Symlin (pramlintide) as an adjunct to insulin

    FDA approved pramlintide injection (Symlin), a synthetic amylin analog, for use with mealtime insulin in type 1 and type 2 diabetes.

    Regulatory: FDA approvedSource: Drugs@FDA: Symlin (pramlintide) NDA 021332

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Pramlintide and the source of each dated event.

  1. [1]FDA prescribing information for Symlin (pramlintide acetate) injection, via DailyMedFDA, 2024
  2. [2]WADA Prohibited ListWADA, 2026
  3. [3]Drugs@FDA: Symlin (pramlintide) NDA 021332FDA, 2005